Genetic testing before commencing standard chemotherapy for gastrointestinal (GI) cancers has emerged as a crucial tool to mitigate treatment toxicities stemming from drug-gene interactions. Research indicates that by identifying variants in specific genes like dihydropyrimidine dehydrogenase (DPYD) and UDP glucuronosyltransferase family 1 member A1 (UGT1A1), healthcare providers can significantly reduce the risk of hospitalizations or emergency department visits due to severe adverse events.
The call to action to “start testing now” comes from experts like Sony Tuteja, a leading figure in pharmacogenomics at the Penn Medicine Center for Genomic Medicine. Tuteja stresses that failure to conduct these genetic tests could lead to inadvertent overdosing in patients with relevant genetic variants, a situation entirely preventable through preemptive screening.
Gastrointestinal malignancies, such as colorectal and pancreatic cancers, are typically treated with fluoropyrimidine antimetabolites and irinotecan. However, individuals carrying DPYD or UGT1A1 variants face a higher risk of adverse reactions to these treatments. Studies have shown that these risks can be mitigated through dose adjustments, prompting regulatory bodies like the European Medicines Agency and the European Society of Medical Oncology to recommend DPYD testing.
Despite these advancements, the integration of genetic testing into clinical practice faced initial resistance in the U.S., primarily due to guideline discrepancies and perceived logistical challenges by healthcare professionals. However, efforts led by institutions like Penn Medicine have successfully streamlined the testing process, from faster turnaround times for results to integrating genetic data into electronic health records for clinical decision support.
A prospective study conducted by Tuteja and colleagues involving 225 GI cancer patients revealed that those who underwent genetic testing had a higher rate of receiving screening results before initiating chemotherapy. This timely information led to significant improvements in managing treatment-related adverse events, including lower rates of severe toxicity, treatment discontinuation, and the need for treatment modifications compared to a control group from a biobank cohort.
Although the study had limitations, such as incomplete toxicity grade data and instances where clinicians proceeded with treatment before receiving screening results, the outcomes underscored the potential of genetic testing to enhance personalized medicine in oncology. Tragically, cases like that of Dr. Anil Kapoor, who experienced adverse events due to a rare variant not covered by standard testing, highlight the importance of ongoing research to uncover additional impactful genetic markers, especially in diverse populations.
Looking ahead, the focus shifts towards broader adoption of genetic testing guided by updated guidelines and regulatory support. The future holds promise for leveraging real-world data to refine chemotherapy dosages based on individual genetic profiles, paving the way for more precise and effective cancer treatments. Beyond chemotherapy, the trajectory of research suggests a shift towards comprehensive genetic sequencing to tailor medications across various therapeutic categories, revolutionizing patient care in the coming years.
Key takeaways:
– Genetic testing before chemotherapy initiation can significantly reduce treatment toxicities for GI cancer patients with relevant genetic variants.
– Streamlining genetic testing processes, integrating results into clinical workflows, and enhancing clinician education are pivotal for maximizing the benefits of personalized medicine.
– Ongoing research efforts should focus on uncovering additional impactful genetic markers, particularly in diverse populations, to improve treatment outcomes and expand the scope of precision medicine in oncology.
– The future of oncology lies in leveraging genetic data to tailor not only chemotherapy but also supportive care medications, heralding a new era of personalized medicine in cancer treatment.
Read more on healio.com